secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001723128-23-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q3 net revenue $620M (+14% YoY); adjusted EBITDA $154M (+22%); guidance raised
--------------------------------------------------------------------------------

- Net revenue $620M (+14% YoY); GAAP net income $10M ($0.06 EPS) vs loss $0.02 in Q3 2022.
- Adjusted net income $60M; adjusted EBITDA $154M (+22%); adjusted EPS $0.19 vs $0.14.
- Generics revenue +12%, AvKARE +25%, Specialty +9%; all segments contributed to growth.
- FY2023 guidance affirmed after previously being raised; on track to launch 40+ generics; IPX203 on track for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/0001723128-23-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312823000038/amrx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001723128-23-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer